ClinicalTrials.gg
CompletedNCT03219437Updated Nov 3, 2022

A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of risankizumab and methotrexate in Psoriasis, sponsored by AbbVie. Completed at 11 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-03.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.

Enrollment
23rd of 30
104 · median 162
Started
2018
with 2 others
Phase 3
17 of 30
none open now
Registered
12th of 30
by date
Lead sponsor
24 of 30
AbbVie

Among the 30 studies testing risankizumab in Psoriasis, this one is the 23rd largest by enrollment, is one of 3 that started in 2018, is one of 17 in phase 3, and was the 12th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About risankizumab

risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing risankizumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to compare the safety and efficacy of risankizumab to methotrexate in participants with moderate to severe plaque psoriasis.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • ABBV-066
  • BI 655066
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of plaque psoriasis (with or without concurrent psoriatic arthritis) for at least 6 months before the first administration of study drug
  • Have stable moderate to severe plaque psoriasis with or without psoriatic arthritis at both Screening and Baseline Visits
  • Be a candidate for systemic therapy for plaque psoriasis as assessed by the investigator
  • Be a candidate for treatment with methotrexate (MTX) according to local label

Exclusion criteria

Exclusion Criteria:

  • Subjects with non-plaque forms of psoriasis, current drug-induced psoriasis, or active ongoing inflammatory diseases other than psoriasis that might confound study evaluations according to investigator's judgment
  • Previous exposure to risankizumab
  • Previous exposure to MTX
  • Use of any prohibited medication or any drug considered likely to interfere with the safe conduct of the study, as assessed by the investigator
  • Subject has a history of hematologic, renal, or liver disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
104 participants (actual)

Study arms

  • Active comparator
    Methotrexate

    Participants to receive double-blind methotrexate.

    Drug: methotrexate

  • Experimental
    Risankizumab

    Participants to receive double-blind risankizumab.

    Drug: risankizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of participants with Static Physician Global Assessment (sPGA) score of clear or almost clear (0, 1) at Week 28.

    The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions.

    Time frame: Week 28

  2. Percentage of participants with a ≥ 90% reduction from Baseline Psoriasis Area and Severity Index (PASI 90) at Week 28

    PASI90 denotes greater than or equal to 90% improvement in PASI score. PASI provides a quantitative assessment of psoriasis disease state based on the amount of body surface area that is affected and the degree of severity of erythema, induration, and scale, weighted by body part.

    Time frame: Week 28

Secondary outcomes

  1. Percentage of participants with a 100% reduction from Baseline PASI score (PASI 100) at Week 28

    PASI100 denotes greater than or equal to 100% improvement in PASI score. PASI provides a quantitative assessment of psoriasis disease state based on the amount of body surface area that is affected and the degree of severity of erythema, induration, and scale, weighted by body part.

    Time frame: Week 28

  2. Percentage of participants with a ≥ 75% reduction from Baseline PASI score (PASI 75) at Week 28

    PASI75 denotes greater than or equal to 75% improvement in PASI score. PASI provides a quantitative assessment of psoriasis disease state based on the amount of body surface area that is affected and the degree of severity of erythema, induration, and scale, weighted by body part.

    Time frame: Week 28

  3. Percentage of participants with Static Physician Global Assessment (sPGA) score of clear (0) at Week 28

    The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions.

    Time frame: Week 28

  4. Change from baseline in EQ-5D-5L at all visits collected

    The EQ-5D-5L is a standardized non-disease specific instrument for describing and valuing health-related quality of life.

    Time frame: Week 28

  5. Achievement of an increase of 0.1 or more points from baseline in European Quality of Life 5 Dimensions (EQ-5D-5L) at all visits

    The EQ-5D-5L has five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. These dimensions are measured on a five-level scale: no problems, slight problems, moderate problems, severe problems, and extreme problems.

    Time frame: Week 28

07

Study locations

11 sites
  • CETI - Centro de Estudos em Terapias Inovadoras /ID# 208593
    Curitiba, Parana 80030-110, Brazil
  • PUC Trials-Nucleo de Pesquisa clinica da Escola de Medicina da PUCPR /ID# 164401
    Curitiba, Parana 80230-130, Brazil
  • Hospital Moinhos de Vento /ID# 208592
    Porto Alegre, Rio Grande Do Sul 90035-001, Brazil
  • Hospital de Clinicas de Porto Alegre /ID# 164565
    Porto Alegre, Rio Grande Do Sul 90035-903, Brazil
  • Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu /ID# 164743
    Botucatu, Sao Paulo 18618-686, Brazil
  • Hospital de Clinicas da Universidade Estadual de Campinas - UNICAMP /ID# 164521
    Campinas, Sao Paulo 13083-888, Brazil
  • Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto - USP /ID# 164768
    Ribeirão Preto, Sao Paulo 14051-140, Brazil
  • Faculdade de Medicina do ABC /ID# 164519
    Santo André, Sao Paulo 09060-870, Brazil
  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 164723
    Sao Jose Do Rio Preto, Sao Paulo 15090-000, Brazil
  • Instituto de Dermatologia e Estética do Brasil /ID# 164754
    Rio de Janeiro, 22470-220, Brazil
  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo /ID# 164805
    Sao Paulo, 05403-000, Brazil
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Nov 2021, 39 months.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 39 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2017
First posted
Jul 17, 2017
StartActual
Jul 30, 2018
Primary completionActual
Nov 26, 2021
CompletionActual
Nov 26, 2021
Last update
Nov 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03219437
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 17, 2017
Start date
Jul 30, 2018
Primary completion
Nov 26, 2021
Completion
Nov 26, 2021
Last update
Nov 3, 2022

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion